Chief Medical Officer of Lincal Accelovance, a global Contract Research Organization capable of delivering large-scale projects, covering all key markets in Asia-Pacific, Europe, and North America. Dr. Goeken brings expertise in designing and running clinical trials, bringing relationships within the biotech R&D ecosystem to the Cytonics’ team.
Dr. LoGrasso is a drug discovery and development expert with 25 years of industrial and academic experience in multiple focus areas, including inflammatory diseases. His three decades of experience with Big Pharma, venture-backed biotech, and hedge fund biotech investing brings deep-seated knowledge into the essential elements of drug development.
22 issued US and
5 pending patents under prosecution covering both APIC and CYT-108 composition and methods of use.
Current patent portfolio is large and multi-fold, covering the methods of use and composition of matter of CYT-108, the APIC therapy, and the FACT diagnostic.
We have built a defensible moat around our technologies that prevent them from being duplicated.
Completed GMP production of CYT-108 for the Phase 1 study. This is the culmination of 5 years’ and $3M worth of research and development!
No subjects experienced adverse events related to the drug
Final dataset will be published in September 2022
The data is in… and CYT-108 appears safe to administer and is capable of repairing cartilage in damaged joints
Our latest safety data shows that any CYT-108 that makes it into the bloodstream is rapidly cleared by antibodies.
These antibodies are produced within 24 hours of CYT-108 injection, and completely prevent CYT-108 from leaking into the blood after multiple injections.
This data further supports the safety profile, and de-risks our Phase 1 safety study!